184 related articles for article (PubMed ID: 23613854)
1. Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.
Chen P; Nogusa S; Thapa RJ; Shaller C; Simmons H; Peri S; Adams GP; Balachandran S
PLoS One; 2013; 8(4):e61446. PubMed ID: 23613854
[TBL] [Abstract][Full Text] [Related]
2. NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.
Thapa RJ; Chen P; Cheung M; Nogusa S; Pei J; Peri S; Testa JR; Balachandran S
Mol Cancer Ther; 2013 Aug; 12(8):1568-78. PubMed ID: 23657944
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Brooks AD; Jacobsen KM; Li W; Shanker A; Sayers TJ
Mol Cancer Res; 2010 May; 8(5):729-38. PubMed ID: 20442297
[TBL] [Abstract][Full Text] [Related]
4. NF-kappaB protects cells from gamma interferon-induced RIP1-dependent necroptosis.
Thapa RJ; Basagoudanavar SH; Nogusa S; Irrinki K; Mallilankaraman K; Slifker MJ; Beg AA; Madesh M; Balachandran S
Mol Cell Biol; 2011 Jul; 31(14):2934-46. PubMed ID: 21576359
[TBL] [Abstract][Full Text] [Related]
5. Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective.
Balachandran S; Adams GP
J Interferon Cytokine Res; 2013 Apr; 33(4):171-80. PubMed ID: 23570383
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.
An J; Rettig MB
Mol Cancer Ther; 2007 Jan; 6(1):61-9. PubMed ID: 17237266
[TBL] [Abstract][Full Text] [Related]
7. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
An J; Sun Y; Fisher M; Rettig MB
Mol Cancer Ther; 2004 Jun; 3(6):727-36. PubMed ID: 15210859
[TBL] [Abstract][Full Text] [Related]
8. Development of interferon γ-based immunocytokines targeting renal cancer.
Chen P; Balachandran S
Oncoimmunology; 2013 Jul; 2(7):e24964. PubMed ID: 24073376
[TBL] [Abstract][Full Text] [Related]
9. IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.
Armstrong MJ; Stang MT; Liu Y; Yan J; Pizzoferrato E; Yim JH
Cancer Biol Ther; 2015; 16(7):1029-41. PubMed ID: 26011589
[TBL] [Abstract][Full Text] [Related]
10. Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma.
Hillman GG; Puri RK; Kukuruga MA; Pontes JE; Haas GP
Clin Exp Immunol; 1994 Jun; 96(3):476-83. PubMed ID: 8004818
[TBL] [Abstract][Full Text] [Related]
11. Interferon-induced RIP1/RIP3-mediated necrosis requires PKR and is licensed by FADD and caspases.
Thapa RJ; Nogusa S; Chen P; Maki JL; Lerro A; Andrake M; Rall GF; Degterev A; Balachandran S
Proc Natl Acad Sci U S A; 2013 Aug; 110(33):E3109-18. PubMed ID: 23898178
[TBL] [Abstract][Full Text] [Related]
12. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line.
Dovhey SE; Ghosh NS; Wright KL
Cancer Res; 2000 Oct; 60(20):5789-96. PubMed ID: 11059775
[TBL] [Abstract][Full Text] [Related]
13. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.
An J; Fisher M; Rettig MB
Oncogene; 2005 Feb; 24(9):1563-70. PubMed ID: 15608669
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.
Lesinski GB; Benninger K; Kreiner M; Quimper M; Young G; Carson WE
Cancer Immunol Immunother; 2009 Dec; 58(12):2031-7. PubMed ID: 19396596
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
Law CL; Gordon KA; Toki BE; Yamane AK; Hering MA; Cerveny CG; Petroziello JM; Ryan MC; Smith L; Simon R; Sauter G; Oflazoglu E; Doronina SO; Meyer DL; Francisco JA; Carter P; Senter PD; Copland JA; Wood CG; Wahl AF
Cancer Res; 2006 Feb; 66(4):2328-37. PubMed ID: 16489038
[TBL] [Abstract][Full Text] [Related]
16. Interferon-α induces G1 cell-cycle arrest in renal cell carcinoma cells via activation of Jak-Stat signaling.
Shang D; Yang P; Liu Y; Song J; Zhang F; Tian Y
Cancer Invest; 2011 Jun; 29(5):347-52. PubMed ID: 21599510
[TBL] [Abstract][Full Text] [Related]
17. Cytokine-stimulated GTP cyclohydrolase I expression in endothelial cells requires coordinated activation of nuclear factor-kappaB and Stat1/Stat3.
Huang A; Zhang YY; Chen K; Hatakeyama K; Keaney JF
Circ Res; 2005 Feb; 96(2):164-71. PubMed ID: 15604419
[TBL] [Abstract][Full Text] [Related]
18. Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.
Shang D; Han T; Xu X; Liu Y
Int J Clin Exp Pathol; 2015; 8(9):11140-8. PubMed ID: 26617834
[TBL] [Abstract][Full Text] [Related]
19. Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C.
Radaeva S; Jaruga B; Kim WH; Heller T; Liang TJ; Gao B
Biochem J; 2004 Apr; 379(Pt 1):199-208. PubMed ID: 14690454
[TBL] [Abstract][Full Text] [Related]
20. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway.
Ji F; Zhang F; Zhang M; Long K; Xia M; Lu F; Li E; Chen J; Li J; Chen Z; Jing L; Jia S; Yang R; Hu Z; Guo Z
J Hematol Oncol; 2021 Sep; 14(1):152. PubMed ID: 34556152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
